From the Department of Nutrition, School of Public Health (C.Y., H.X., L.W., Q.C., X.C., W.L.).
Center for Health Examination, the Third Affiliated Hospital (C.Y.).
Circ Res. 2018 Sep 28;123(8):996-1007. doi: 10.1161/CIRCRESAHA.118.313558.
Bioavailable and free 25-hydroxyvitamin D (25(OH)D) are emerging measurements of vitamin D. Whether serum bioavailable or free 25(OH)D level is associated with mortality in patients with coronary artery disease (CAD) is unknown.
Our aim is to determine the potential association between serum total, bioavailable, and free 25(OH)D levels and the risk of mortality among patients with CAD.
We measured serum 25(OH) levels in 1387 patients with angiographically confirmed CAD from the Guangdong Coronary Artery Disease Cohort. Serum DBP (vitamin D-binding protein) levels were measured using a polyclonal immunoassay, and serum-free 25(OH)D levels were measured using a 2-step immunoassay. Bioavailable 25(OH)D levels were calculated using a previously validated formula. By the median follow-up time of 6.7 years, 205 patients had died, including 134 deaths from cardiovascular diseases. In multivariate analyses, low serum bioavailable 25(OH)D level was significantly associated with increased risks of mortality, independent of established cardiovascular risk factors, features and treatments of CAD, factors associated with vitamin D and mineral metabolism, and CRP (C-reactive protein). The multivariable-adjusted hazard ratios across quartiles of bioavailable 25(OH)D were 1.79, 1.35, 1.36, and 1.00 for all-cause mortality ( P for trend=0.01) and 2.58, 1.85, 1.73, and 1.00 for cardiovascular mortality ( P for trend=0.001), respectively. Serum-free 25(OH)D level was inversely associated with the risk of mortality, with the extreme-quartile hazard ratios of 1.64 for all-cause mortality ( P for trend=0.024) and 1.97 for cardiovascular mortality ( P for trend=0.013). In contrast, serum total 25(OH)D level was not significantly associated with all-cause mortality or cardiovascular mortality.
Lower serum bioavailable and free 25(OH)D levels rather than total 25(OH)D level are independently associated with an increased risk of all-cause mortality and cardiovascular mortality in a population-based CAD cohort.
生物可利用的和游离的 25-羟维生素 D(25(OH)D)是维生素 D 的新兴测量指标。血清生物可利用的或游离的 25(OH)D 水平与冠心病(CAD)患者的死亡率之间是否存在关联尚不清楚。
我们的目的是确定血清总 25(OH)D、生物可利用的 25(OH)D 和游离 25(OH)D 水平与 CAD 患者死亡风险之间的潜在关联。
我们从广东冠状动脉疾病队列中测量了 1387 例经血管造影证实的 CAD 患者的血清 25(OH) 水平。使用多克隆免疫测定法测量血清 DBP(维生素 D 结合蛋白)水平,使用两步免疫测定法测量血清游离 25(OH)D 水平。使用先前验证的公式计算生物可利用的 25(OH)D 水平。在中位数为 6.7 年的随访期间,205 名患者死亡,其中 134 名死于心血管疾病。在多变量分析中,低血清生物可利用的 25(OH)D 水平与死亡率增加显著相关,独立于已建立的心血管危险因素、CAD 的特征和治疗、与维生素 D 和矿物质代谢相关的因素以及 CRP(C 反应蛋白)。按生物可利用的 25(OH)D 四分位数划分的多变量调整后的风险比分别为:全因死亡率为 1.79、1.35、1.36 和 1.00(趋势 P=0.01),心血管死亡率为 2.58、1.85、1.73 和 1.00(趋势 P=0.001)。血清游离 25(OH)D 水平与死亡率呈负相关,全因死亡率的极端四分位数风险比为 1.64(趋势 P=0.024),心血管死亡率的风险比为 1.97(趋势 P=0.013)。相比之下,血清总 25(OH)D 水平与全因死亡率或心血管死亡率无显著相关性。
在基于人群的 CAD 队列中,较低的血清生物可利用的和游离 25(OH)D 水平而非总 25(OH)D 水平与全因死亡率和心血管死亡率增加独立相关。